文献速递湿疹皮炎与荨麻疹

含神经酰胺与丝聚蛋白相关氨基酸润肤剂预防高危婴儿特应性皮炎的随机对照试验

A randomized controlled trial of an emollient with ceramide and filaggrin-associated amino acids for the primary prevention of atopic dermatitis in high-risk infants.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2019-07-30

单中心、研究者盲法随机对照试验纳入有家族史的高危婴儿,比较每日全身使用含神经酰胺与氨基酸润肤剂与标准护肤对12月龄累积AD发病率的影响。实际入组100例(目标208例),失访28%;12月龄AD诊断率13.2% vs 25.0%(P=0.204),2岁时19.4% vs 31.0%(P=0.296),趋势利于干预但未达统计学显著。

要点

  • 每日全身使用含神经酰胺与氨基酸润肤剂在12月龄和2岁时AD发病率数值上低于对照,但差异无统计学意义。
  • 皮肤屏障、天然保湿因子及微生物组评估两组间无显著差异。
  • 干预组报告接触性皮炎多于对照(9.3% vs 4.3%),但与研究润肤剂无关且多为轻度。

核心结论

  • 观察到的趋势提示每日使用研究润肤剂相比对照可能具有保护作用,但因样本量不足未达统计学显著。

研究设计与样本

  • 单中心、研究者盲法随机对照试验,纳入依据家族史判定的AD高危婴儿,目标样本208例,实际入组100例,失访28%。
  • 干预为每日一次全身涂抹含神经酰胺与氨基酸的研究润肤剂,对照不规律全身使用润肤剂、仅在皮肤干燥时自选润肤剂。
  • 主要结局为12月龄时由盲法研究者诊断的AD累积发病率。

主要发现

  • 12月龄AD诊断率干预组13.2% vs 对照组25.0%(P=0.204)。
  • 2岁时AD诊断率干预组19.4% vs 对照组31.0%(P=0.296)。
  • 皮肤屏障、天然保湿因子及微生物组评估两组间无显著差异。
  • 干预组报告接触性皮炎9.3% vs 对照组4.3%,均与研究润肤剂无关且多为轻度,无严重不良事件。

临床怎么用

  • 对AD高危婴儿,每日全身使用含神经酰胺与氨基酸的润肤剂在数值上可能降低AD发病率,但现有证据不足以确立推荐。
  • 使用过程中需关注接触性皮炎等不良反应,多数为轻度。

局限性

  • 实际入组仅100例,低于目标208例,失访28%,统计效力不足。
  • 单中心设计,结果外推受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Skin barrier dysfunction may precede infantile development of clinical atopic dermatitis (AD). Early-life emollient therapy to enhance barrier function may prevent or modify AD development in high-risk infants. OBJECTIVES: (a) To determine whether daily full-body application of an emollient with ceramide and amino acids (study emollient) can reduce the cumulative AD incidence compared to standard skin care at 1 year of age. (b) To evaluate the study emollient's effect on skin barrier function, natural moisturizing factor and the microbiome using non-invasive biophysical and biochemical techniques. METHODS: We performed a single-centre, investigator-blinded, randomized controlled trial enrolling infants at high risk for AD development determined by family history. The intervention was full-body once-daily application of the study emollient. The control arm was asked to not apply full-body emollient regularly and only use an emollient of their choice for dry skin. The primary outcome was the cumulative incidence of AD diagnosed at 12 months by a blinded investigator. RESULTS: Less than half the target sample size was enrolled (n = 100, goal sample was 208) with 28% lost to follow-up. Across all clinical end points, a numerical trend was observed in favour of the intervention, although not statistically significant likely due to lack of power from under-enrolment. AD was diagnosed in 13.2% vs. 25.0% at 12 months (P = 0.204) and 19.4% vs. 31.0% at 2 years (P = 0.296) in intervention vs. control groups, respectively. There were no significant differences between groups in skin barrier or microbiome assessments. While there were no serious adverse events, there were more cases of reported contact dermatitis in the intervention vs. control arms, 9.3% vs. 4.3%, respectively; however, these events were not related to the study emollient and most mild in severity. CONCLUSION: The observed trends suggest a protective effect of daily study emollient therapy compared to control.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. McClanahan D, Wong A, Kezic S, et al. A randomized controlled trial of an emollient with ceramide and filaggrin-associated amino acids for the primary prevention of atopic dermatitis in high-risk infants. J Eur Acad Dermatol Venereol. 2019. PMID: 31287580. doi:10.1111/jdv.15786

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。